Carefully Phenotyped Changes in Neuropathy Measures with Exposure to Neurotoxic Chemotherapy (P4.231)

Conclusions:CIPN occurs in 50[percnt] of at risk patients. The clinical severity of CIPN is related to cumulative chemotherapy dose. Assessment of sudomotor function using Sudoscan was significantly correlated with CIPN specific quality of life. These findings promise to inform design of future clinical trials of potential preventative therapies.Disclosure: Dr. Kolb has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Singleton has nothing to disclose. Dr. Smith has received personal compensation for activities with CSL Behring, Grifols, and Allergan. Dr. Smith has received research support from NIH, the ADA, and Impeto. Dr. Smith has received personal compensation in an editorial capacity for NeuroLear

Source: Neurology - April 3, 2016 Category: Neurology Authors: Kolb, N., Brown, S., Singleton, J., Smith, A. G. Tags: Neuro-oncology: Neurologic Complications of Cancer Source Type: research